osimertinib
astrazeneca
['herb', 'osimertinib', 'nsclc', 'sclc']
 osimertinib is the first targeted therapy to show significant os benefit in the adjuvant setting," said roy s. herbst, md, phd. #nsclc #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.